BioPharmSignal logoBioPharmSignal

Biotech News

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio (INAB)IN8bioCompany update

NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the

Related news

INABIN8bio2026-11-05 21:01 EST

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

KPTIKaryopharm Therapeutics2026-10-01 20:05 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ANGOAngioDynamics2026-11-06 23:00 EST

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-11-06 12:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-11-03 21:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-11-02 22:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-10-30 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-10-19 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMPXCompass Therapeutics2026-10-14 20:30 EST

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

View all latest news

IN8bio

Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...

Recent company news

INABIN8bio2026-11-06 21:01 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-11-05 21:01 EST

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

INABIN8bio2026-10-06 20:00 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-09-22 20:00 EST

IN8bio to Present at Sidoti Small-Cap Virtual Conference

INABIN8bio2026-09-10 12:00 EST

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
0.83 USD
Market cap
14.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States